Habitual coffee consumption and risk of type 2 diabetes, ischemic heart disease, depression and Alzheimer’s disease: a Mendelian randomization study

Man Ki Kwok¹, Gabriel M. Leung¹ & C. Mary Schooling¹,²

Observationally, coffee is inversely associated with type 2 diabetes mellitus (T2DM), depression and Alzheimer’s disease, but not ischemic heart disease (IHD). Coffee features as possibly protective in the 2015 Dietary Guidelines for Americans. Short-term trials suggest coffee has neutral effect on most glycemic traits, but raises lipids and adiponectin. To clarify we compared T2DM, depression, Alzheimer’s disease, and IHD and its risk factors by genetically predicted coffee consumption using two-sample Mendelian randomization applied to large extensively genotyped case-control and cross-sectional studies. Childhood cognition was used as a negative control outcome. Genetically predicted coffee consumption was not associated with T2DM (odds ratio (OR) 1.02, 95% confidence interval (CI) 0.76 to 1.36), depression (0.89, 95% CI 0.66 to 1.21), Alzheimer’s disease (1.17, 95% CI 0.96 to 1.43), IHD (0.96, 95% CI 0.80 to 1.14), lipids, glycemic traits, adiposity or adiponectin. Coffee was unrelated to childhood cognition. Consistent with observational studies, coffee was unrelated to IHD, and, as expected, childhood cognition. However, contrary to observational findings, coffee may not have beneficial effects on T2DM, depression or Alzheimer’s disease. These findings clarify the role of coffee with relevance to dietary guidelines and suggest interventions to prevent these complex chronic diseases should be sought elsewhere.

Coffee is habitually consumed in Western societies. Adults in the United States and many European countries typically drink 2 to 3 cups of coffee a day¹,². With economic development coffee consumption is becoming more common in Asia including South Korea, China and India. Coffee is believed by the general public to have no benefits for type 2 diabetes mellitus (T2DM) or cognitive decline, but to increase the risk of cardiovascular disease (CVD)³. In contrast, coffee features in the latest 2015 Dietary Guidelines for Americans as something that might be healthy⁴. Observationally, coffee (both regular and decaffeinated) is monotonically associated with lower risk of type 2 diabetes mellitus (T2DM)⁵. Coffee is also associated with lower risk of depression⁶, as substantiated in a large prospective cohort study of older adults in the United States⁷, as well as of Alzheimer’s disease⁸. Coffee consumption is not clearly associated with ischemic heart disease (IHD)⁹, although moderate coffee drinking may be associated with slightly lower risk¹⁰. However, observational studies are open to biases from residual confounding by incompletely measured factors that may have major influences on lifestyle and health, such as socio-economic position and health status. Meta-analyses of randomized controlled trials (RCTs) suggest short-term coffee consumption raises triglycerides and low-density lipoprotein (LDL) cholesterol¹¹. A small RCT found that short-term coffee consumption increased adiponectin¹², which may relate to lower CVD risk¹³. Several RCTs showed short-term coffee consumption had no effect on fasting glucose, fasting insulin or insulin resistance¹²,¹⁴,¹⁵, although one RCT found it slightly increased glycosylated hemoglobin (HbA1c)¹⁶. The lack of evidence from long-term RCTs means that the effects of coffee on health are unclear, but are particularly important to establish in this window of opportunity before habitual coffee drinking extends to become the global norm.

¹School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China. ²City University of New York Graduate School of Public Health and Health Policy, New York, United States. Correspondence and requests for materials should be addressed to C.M.S. (email: cms1@hku.hk)
In this situation, comparing health by genetically predicted coffee consumption, i.e., using Mendelian randomization (MR), may help clarify the causal effect of coffee on health by generating unbiased estimates from observational studies because MR is less prone to confounding and reverse causality. To date, one MR study, using large cohort studies from Denmark, found no association of genetically predicted coffee consumption with T2DM or CVD risk factors including triglycerides, high-density lipoprotein (HDL) cholesterol, non-fasting glucose, waist circumference and body mass index (BMI). However, the study was underpowered to assess the effect of coffee on CVD risk factors and did not assess the effect on IHD. To clarify the role of coffee in health, we assessed the role of coffee consumption in T2DM, IHD, CVD risk factors (lipids, glycemic traits, adiposity and adiponectin), depression and Alzheimer’s disease using genetic determinants of coffee from genome-wide association studies (GWAS) applied to very large extensively genotyped case-control and cross-sectional studies. We used childhood cognition as a negative control outcome because coffee unlikely affects cognition in childhood, given coffee drinking usually becomes a habit after adolescence.

### Results

**Genetically predicted coffee consumption.** Table 1 shows ten single nucleotide polymorphisms (SNPs) were associated with habitual coffee consumption (number of cups per day) at genome-wide significant (log₁₀ Bayes Factor > 5.64 which approximates P < 5 × 10⁻⁸) and linkage disequilibrium (r² > 0.8). Abbreviations: MR, Mendelian randomization; SNP, single nucleotide polymorphisms. rs17685 was not available for type 2 diabetes mellitus and lipids, so rs8565 was used instead because it was highly correlated with rs17685 (r² = 0.845), in close proximity (distance within 25 kb of rs17685), and had similar allele frequency (HapMap CEU: rs8565 A (0.29) and rs17685 A (0.30)) and similar genetic association for ischemic heart disease. rs2470893 and rs7800944 were not available for cognition. For rs2470893, rs2472297 was used instead because it was highly correlated with rs2470893 (r² = 0.694), in close proximity (distance within 10 kb of rs2470893) and had similar allele frequency (HapMap CEU: rs2472297 T (0.25) and rs2470893 T (0.26)). For rs7800944, rs14415 was used instead because it was highly correlated with rs7800944 (r² = 0.816), in close proximity (distance within 100 kb of rs7800944) and had similar allele frequency (HapMap CEU: rs4410790 T (0.25) and rs2470893 T (0.26)). rs6968554 reaches genome-wide significance but was excluded from the analyses because of linkage disequilibrium with rs4410790 and large P value. Reference: The Coffee and Caffeine Genetics Consortium, Cornelis MC, Byrne EM, Esko T, Nalls MA, Ganna A et al. Genome-wide meta-analysis identifies six novel loci associated with habitual coffee consumption. Mol Psychiatry. 2015; 20:647–56. Pleiotropy was identified using Ensembl (Homo sapiens – phenotype) (http://grch37.ensembl.org/Homo_sapiens/Info/Index).

### Table 1

| SNP       | Locus    | Closest gene | Effect allele | Non-effect allele | Allelic frequency | Habitual coffee consumption | Pleiotropy |
|-----------|----------|--------------|---------------|-------------------|-------------------|-----------------------------|------------|
| rs6265    | 11p13    | BDNF         | C             | T                 | 0.18              | 0.071                       | 0.046      |
| rs17685*  | 7q11.23  | POR          | A             | G                 | 0.30              | 0.191                       | 0.070      |
| rs1260326 | 2p24     | GCKR         | C             | T                 | 0.36              | 0.171                       | 0.044      |
| rs1481012 | 4q22     | ABCG2        | A             | G                 | 0.89              | 0.951                       | 0.061      |
| rs2470893** | 15q24   | CYP1A2       | T             | C                 | 0.32              | 0.061                       | 0.121      |
| rs4410790 | 7p21     | AHR          | C             | T                 | 0.35              | 0.521                       | 0.101      |
| rs9902453 | 17q11.2  | EFCAB5       | G             | A                 | 0.39              | 0.301                       | 0.131      |
| rs8565    | 7q11.23  | POR          | A             | G                 | 0.30              | 0.191                       | 0.071      |
| rs17685   | 11p13    | BDNF         | C             | T                 | 0.18              | 0.071                       | 0.046      |
| rs6265    | 11p13    | BDNF         | C             | T                 | 0.18              | 0.071                       | 0.046      |
| rs17685*  | 7q11.23  | POR          | A             | G                 | 0.30              | 0.191                       | 0.070      |
| rs1260326 | 2p24     | GCKR         | C             | T                 | 0.36              | 0.171                       | 0.044      |
| rs1481012 | 4q22     | ABCG2        | A             | G                 | 0.89              | 0.951                       | 0.061      |
| rs2470893** | 15q24   | CYP1A2       | T             | C                 | 0.32              | 0.061                       | 0.121      |
| rs4410790 | 7p21     | AHR          | C             | T                 | 0.35              | 0.521                       | 0.101      |
| rs9902453 | 17q11.2  | EFCAB5       | G             | A                 | 0.39              | 0.301                       | 0.131      |

In this situation, comparing health by genetically predicted coffee consumption, i.e., using Mendelian randomization (MR), may help clarify the causal effect of coffee on health by generating unbiased estimates from observational studies because MR is less prone to confounding and reverse causality. To date, one MR study, using large cohort studies from Denmark, found no association of genetically predicted coffee consumption with T2DM or CVD risk factors including triglycerides, high-density lipoprotein (HDL) cholesterol, non-fasting glucose, waist circumference and body mass index (BMI). However, the study was underpowered to assess the effect of coffee on CVD risk factors and did not assess the effect on IHD. To clarify the role of coffee in health, we assessed the role of coffee consumption in T2DM, IHD, CVD risk factors (lipids, glycemic traits, adiposity and adiponectin), depression and Alzheimer’s disease using genetic determinants of coffee from genome-wide association studies (GWAS) applied to very large extensively genotyped case-control and cross-sectional studies. We used childhood cognition as a negative control outcome because coffee unlikely affects cognition in childhood, given coffee drinking usually becomes a habit after adolescence.
were used instead because they are highly correlated with the original SNPs (rs2472297: $r^2 = 0.694$; rs14415: $r^2 = 0.816$), in close proximity (rs2472297: distance within 10 kb of rs2470893; rs14415: distance within 100 kb of rs7800944) and had a similar allele frequency (HapMap CEU: rs2472297 T (0.25) and rs2470893 T (0.26); rs2286276 T (0.30) and rs7800944 T (0.29)).

Table 2 shows genetically predicted coffee consumption was not clearly associated with T2DM, IHD, depression or Alzheimer's disease both including and excluding SNPs with known pleiotropy. Most of the estimates were close to the null, particularly after excluding potentially pleiotropic SNPs, although the estimate for Alzheimer's disease was in a positive direction. Coffee consumption was not clearly associated with most CVD risk factors (lipids, glycemic traits, BMI, WHR and adiponectin) particularly after excluding SNPs with known pleiotropy, although the estimates for LDL-cholesterol, BMI, WHR and adiponectin were in a positive direction. Coffee was unrelated to childhood cognition. An analysis using only the 3 functionally relevant SNPs gave a similar pattern of associations. Not using rs8565 as a replacement for rs17685 gave a very similar pattern of associations (data not shown). The associations remained similar after adjustment for multiple comparison (data not shown).

**Discussion**

Consistent with the previous smaller MR study using five SNPs for coffee, we found little evidence of coffee being clearly related to T2DM or major CVD risk factors (HDL-cholesterol, LDL-cholesterol, triglycerides and BMI), although we cannot rule out the possibility of coffee raising LDL-cholesterol, BMI, WHR and adiponectin. Our study adds by replicating these findings in larger samples using more SNPs for coffee and showing coffee was also most likely unassociated with IHD and with glycemic traits, consistent with most but not all RCTs. This study also adds by showing coffee most likely unrelated to depression and Alzheimer's disease, although we cannot exclude the possibility that coffee increases the risk of Alzheimer's disease. Coffee was unrelated to childhood cognition as expected.
| Outcomes                        | Consortium          | All genome-wide significant SNPs* | 5 SNPs without known pleiotropy related to body weight or lipids† | 3 functionally relevant SNPs* |
|--------------------------------|---------------------|----------------------------------|---------------------------------------------------------------|------------------------------|
|                                |                     | Odds ratio | 95% CIs | Odds ratio | 95% CIs | Odds ratio | 95% CIs |
| Diseases                       |                     |           |        |            |        |            |        |
| Type 2 diabetes mellitus*      | DIAGRAM             | 1.20      | 1.00, 1.42 | 1.03      | 0.81, 1.31 | 1.05      | 0.70, 1.55 |
| Ischemic heart disease         |                     |           |        |            |        |            |        |
|                               | CARDioGRAMplusCAD   | 1.06      | 0.94, 1.20 | 1.07      | 0.91, 1.26 | 1.12      | 0.84, 1.49 |
|                               | Metabochip/CARDioGRAM | 0.96      | 0.84, 1.10 | 0.96      | 0.80, 1.14 | 0.97      | 0.73, 1.30 |
|                               | Pooled              | 1.02      | 0.93, 1.12 | 1.02      | 0.92, 1.13 | 1.05      | 0.94, 1.17 |
| Depression                     |                     |           |        |            |        |            |        |
|                               | PGC                 | 0.89      | 0.66, 1.21 | NA        | 0.95      | 0.47, 1.91 |
| Alzheimer's disease            |                     |           |        |            |        |            |        |
|                               | IGAP                | 1.17      | 0.96, 1.43 | NA        | 1.29      | 0.82, 2.03 |
| Cardiovascular disease risk factors |       |           |        |            |        |            |        |
| HDL-cholesterol (SD)*          | GLGC                | 0.04      | −0.01, 0.09 | −0.02      | −0.09, 0.05 | −0.02     | −0.13, 0.10 |
| LDL-cholesterol (SD)*          | GLGC                | 0.01      | −0.04, 0.06 | 0.06      | −0.01, 0.14 | 0.05      | −0.07, 0.17 |
| Triglycerides (SD)*            | GLGC                | −0.26     | −0.31, −0.21 | 0.02      | −0.05, 0.08 | −0.004    | −0.11, 0.10 |
| Body mass index (SD)           | GIANT               | 0.12      | 0.08, 0.17 | 0.05      | −0.005, 0.11 | 0.05      | −0.04, 0.15 |
| Waist-hip ratio (SD)           | GIANT               | 0.05      | 0.004, 0.10 | 0.06      | −0.01, 0.12 | 0.06      | −0.05, 0.16 |
| HbA1c (%)                      | MAGIC               | 0.03      | −0.02, 0.08 | 0.01      | −0.05, 0.08 | 0.02      | −0.09, 0.13 |
| Fasting glucose (mmol/L)       | MAGIC               | 0.04      | 0.01, 0.08 | −0.01     | −0.06, 0.03 | −0.02     | −0.09, 0.05 |
| Fasting insulin (log-transformed) | MAGIC             | 0.02      | −0.02, 0.06 | −0.03     | −0.09, 0.02 | −0.03     | −0.11, 0.15 |
| β-cell function (log-transformed) | MAGIC             | 0.03      | −0.02, 0.07 | 0.03      | −0.04, 0.09 | 0.04      | −0.06, 0.15 |
| Insulin resistance (log-transformed) | MAGIC | 0.06      | 0.0005, 0.12 | 0.03      | −0.05, 0.10 | 0.04      | −0.09, 0.17 |
| Adiponectin (log-transformed)  | ADIPOGen            | 0.04      | −0.02, 0.10 | 0.04      | −0.04, 0.12 | 0.03      | −0.11, 0.17 |
| Control outcome                |                     |           |        |            |        |            |        |
|                                | SSGAC               | 0.07      | −0.09, 0.23 | NA        | 0.10      | −0.26, 0.45 |

Table 2. Association of genetically predicted habitual coffee consumption with type 2 diabetes mellitus, ischemic heart disease, cardiovascular disease risk factors, depression and Alzheimer’s disease obtained from Mendelian randomization analyses using weighted generalized linear regression. Bold indicates statistical significance (P < 0.05). Abbreviations: CI, confidence interval; HbA1c, glycosylated hemoglobin; HDL-cholesterol, high-density lipoprotein cholesterol; LDL-cholesterol, low-density lipoprotein cholesterol; NA, not applicable; SD, standard deviation; SNP, single nucleotide polymorphisms. *rs71685 was not available for type 2 diabetes mellitus and lipids, so rs8565 was used instead because it was highly correlated with rs17685 (r² = 0.845), in close proximity (distance within 25 kb of rs17685), had similar allele frequency (HapMap CEU: rs71685 T (0.30) and rs17685 A (0.30)) and similar genetic association for ischemic heart disease. †rs2470893 and rs7800944 were not available for cognition. For rs2470893, rs2472297 was used instead because it was highly correlated with rs2470893 (r² = 0.694), in close proximity (distance within 10 kb of rs2470893) and had similar allele frequency (HapMap CEU: rs2470893 T (0.29) and rs7800944 T (0.29)). **rs2470893 was not available for childhood cognition. *All SNPs included for analyses were rs6265, rs17685, rs1260326, rs1481012, rs2470893, rs2472297, rs4410790, rs7800944 and rs9902453; SNPs without known pleiotropy included for analyses were rs17685, rs2470893, rs2472297, rs4410790, rs2472297, rs4410790 and rs9902453; and functionally relevant SNPs included for analyses. This large MR study taking advantage of publicly available ‘big data’ provides more precise estimates with greater statistical power because of the large sample sizes and less susceptibility to weak instrument bias from using 9 SNPs which reduces the possibility of false positives. Nonetheless, limitations exist. First, MR estimates could be confounded by population stratification23. We used genetic determinants of coffee from people of predominantly European ancestry (94%) and genetic associations with diseases or its risk factors from people almost exclusively of European ancestry with estimates adjusted for genomic control. In addition, genetic variants predicting coffee are not known to vary geographically within these populations29, unlike another beverage, milk, whose genetic determinant, lactase persistence, has a north–south gradient24. As such, our MR estimates are unlikely confounded by population stratification. Second, effects of genetic determinants of coffee via pathways other than through coffee intake may generate a bias (by violating the exclusion-restriction assumption)25. However, MR estimates with and without pleiotropic SNPs were fairly similar and we placed greater emphasis on the estimates without pleiotropic SNPs. We might have missed some pleiotropic effects because we could only identify known effects and current understanding of the underlying causal pathways. Nonetheless, 3
non-pleiotropic SNPs (rs4410790, rs2472297 and rs2470893) are known to be functionally relevant to coffee metabolism. An analysis using only these SNPs gave broadly similar results. Third, the genetic variants for coffee were associated with number of cups of coffee per day among coffee drinkers, and the estimates would not relate to the effects of coffee if coffee drinking was uncommon in the samples with the outcomes. However, the populations with the outcomes are from the United States or European countries where coffee drinking is typical. Fourth, we cannot rule out the possibility of a non-linear effect of coffee, although that would require a more complex biological explanation. Fifth, the effect of coffee may vary by sex, given a cohort study found coffee consumption was associated with lower risk of cognitive decline in women but not in men. Whether habitual coffee consumption affects health differently by age, sex or baseline coffee consumption could not be tested because genetic associations with coffee and with the outcomes were obtained from separate samples; however the effects of causal factors are generally consistent, although sex-specific mechanistic pathways are possible. Sixth, we used genetic variants for habitual coffee consumption among coffee drinkers. Whether the findings generalize to ever/never coffee drinkers remains elusive, although extrapolating associations from very infrequent coffee drinkers to never coffee drinkers may be reasonable. Seventh, given coffee drinking usually starts in adulthood, developmental canalization buffering the genetic effects as a compensatory mechanism is unlikely to affect interpretation of the MR estimates. Eighth, participants in the studies used may have taken medication for chronic diseases, although genetic associations with lipids and glycemic traits were based on participants not taking relevant medication. However, medication use is unlikely to confound the association of genetic variants with the outcomes, because genetic variants are allocated at conception and precede medication use. Medication use might make the association of genetic variants with coffee consumption less precise. As such, medication use could bias the MR estimate away from the null, hence MR estimates are best interpreted as indicating direction rather than exact effects, particularly for estimates that differ from those not measured in the samples with the outcomes, two-sample MR generates approximate estimates by assuming the genetic associations for coffee are similar in the samples of genetic determinants of coffee and the outcomes. Nonetheless, separate sample MR is more robust to chance findings than single-sample MR because it reduces the possibility of confounding by some cryptic data structure in the single sample.

Unlike previous observational studies, our study, as well as the previous smaller MR study, did not find coffee consumption associated with lower risk of T2DM. Also, unlike some prospective cohort studies, we found no association of coffee consumption with IHD. Such discrepancies might be partly explained by over-adjustment for potentially harmful mediators, such as BMI or lipids, and the inevitable confounding in observational studies. For CVD risk factors, as in the other MR study, we found little evidence of an association of coffee with HDL-cholesterol or triglycerides. The associations of coffee with LDL-cholesterol and adiponectin are directionally consistent with those found in RCTs, but do not exclude no association. We also found no association of coffee with HbA1c, fasting glucose, fasting insulin, beta-cell function or insulin resistance, consistent with most but not all RCTs. In addition, trends in coffee consumption do not coincide with the changing patterns of IHD or T2DM, for example IHD declined but DM rose in the United States where coffee consumption was stable in the past decade. Taken together, the overall lack of association of coffee with T2DM, IHD and many CVD risk factors are coherent within this study, and suggest that coffee has likely minor effects, if any, on these conditions.

Our MR study has some consistency with RCTs, although an MR study tests a causal pathway rather than an intervention. Findings from MR give the lifetime effect of coffee and may be more relevant to the health implications of coffee than findings from RCTs evaluating the short-term effect of a coffee intervention. Nonetheless, replication in a larger sample would be valuable. Our findings, using genetic variants for ‘regular’ coffee, i.e., coffee without decaffeination and/or filtration, do not exclude the possibility of coffee raising LDL cholesterol. Coffee has been thought to have cholesterol-raising effects due to the presence of diterpenes (cafestol and kahweol), and without decaffeination and/or filtration, do not exclude the possibility of coffee raising LDL cholesterol. Coffee replication in a larger sample would be valuable. Our findings, using genetic variants for ’regular’ coffee, i.e., coffee without decaffeination and/or filtration, do not exclude the possibility of coffee raising LDL cholesterol.

The associations of coffee with HbA1c, fasting glucose, fasting insulin, beta-cell function or insulin resistance, consistent with most but not all RCTs. In addition, trends in coffee consumption do not coincide with the changing patterns of IHD or T2DM, for example IHD declined but DM rose in the United States where coffee consumption was stable in the past decade. Taken together, the overall lack of association of coffee with T2DM, IHD and many CVD risk factors are coherent within this study, and suggest that coffee has likely minor effects, if any, on these conditions.

Our MR study has some consistency with RCTs, although an MR study tests a causal pathway rather than an intervention. Findings from MR give the lifetime effect of coffee and may be more relevant to the health implications of coffee than findings from RCTs evaluating the short-term effect of a coffee intervention. Nonetheless, replication in a larger sample would be valuable. Our findings, using genetic variants for ‘regular’ coffee, i.e., coffee without decaffeination and/or filtration, do not exclude the possibility of coffee raising LDL cholesterol. Coffee has been thought to have cholesterol-raising effects due to the presence of diterpenes (cafestol and kahweol), and such effect is usually removed only when coffee is filtered. Several SNPs functionally relevant to coffee regulate the cytochrome P-450 (CYP) enzyme, which may have implications for CVD risk, but includes a large family of enzymes with different functions. The aryl hydrocarbon receptor (AHR) and CYP1A2 (rs2472297) is primarily responsible for metabolizing caffeine and CYP1A1 (rs2470893) metabolizes polycyclic aromatic hydrocarbons, another key ingredient of coffee. CYP1A1 and CYP1A2 knockout mice have lower cholesterol and higher hepatic triglycerides in response to high-fat diet. However, SNPs from CYP1A1/2 have not been found in GWAS of CVD or diabetes, consistent with the lack of association with these two conditions.

This study adds by showing no protective association of habitual coffee consumption with depression or Alzheimer’s disease, contrary to meta-analyses of observational studies where coffee is associated with lower risk. These findings are consistent with null association of coffee with childhood cognition (control outcome). Observed associations of coffee with (particularly subjective measures of) mental health are prone to confounding by socioeconomic position and related attributes (diet and lifestyle), underlying physical health status, and reverse causality. However, the potentially positive association of coffee with Alzheimer’s disease does warrant further investigation. Coffee drinking habits may have changed over time; observationally increasing coffee consumption is associated with higher risk of mild cognitive impairment, while constant moderate coffee consumption is associated with lower risk. Hence, we cannot rule out the possibility that our finding was generated by increased coffee consumption as self-medication for cognitive lapses, although use of genetically predicted coffee consumption should reduce such ‘reverse causality’. Previous observational studies suggest coffee as a modifiable lifestyle factor that may be associated with lower risk of cognitive impairment/decline, although not across all studied cognitive domains. In addition, cohort studies with more complete follow-up tended to observe weaker negative or positive associations of coffee with dementia. Our MR findings raise a question as to the role of coffee in Alzheimer’s disease, which requires replication, so as to clarify the role of coffee as a potential intervention. Coffee consumption has been associated with smaller volume of the hippocampus and poor memory function. EFCABS (rs9902453) is a newly identified SNP for coffee, downstream of SLC6A4, which encodes the...
serotonin transporter and could reduce circulating serotonin\textsuperscript{53}, which might be related to Alzheimer's disease\textsuperscript{54}. Better understanding of whether and how serotonin regulation counteracts neurotoxicity reduction by caffeine induced blockage of adenosine A2 receptor\textsuperscript{23} or other non-coffee components including chlorogenic acids that have been associated with lower risks of dementia\textsuperscript{48} would help clarify the etiology.

In summary, habitual coffee consumption may not have the beneficial effects on IHD, T2DM, most CVD risk factors, depression and Alzheimer's disease suggested by observational studies, instead our study raises the possibility that coffee could increase the risk of Alzheimer's disease and possibly have some unfavourable effects on lipids. This study demonstrates the pitfalls of formulating dietary recommendations based on observational evidence\textsuperscript{23} and emphasizes the importance of genetic validation of potential targets of intervention before making policy or testing interventions\textsuperscript{26}.

**Methods**

**Genetically predicted coffee consumption.** Genetically predicted coffee consumption was based on single nucleotide polymorphisms (SNPs) of genome-wide significant ($P < 5 \times 10^{-8}$). Highly correlated SNPs (high linkage disequilibrium ($r^2 > 0.8$)) were discarded based on larger $P$ value with the correlations taken from SNP Annotation and Proxy Search (SNAP) (www.broadinstitute.org/mpg/snap/idsearchpw.php) using the relevant catalog. SNPs potentially affecting an outcome directly rather than via coffee consumption (pleiotropic effects) were identified from Ensembl (Homo sapiens – phenotype) (http://grch37.ensembl.org/Homo_sapiens/info/Index). Any SNP for coffee not available for an outcome was replaced with a highly correlated SNP ($r^2 > 0.8$).

**Genetically predicted T2DM, IHD, CVD risk factors, depression and Alzheimer’s disease.** Genetic associations for T2DM were obtained from the DiaBetes Replication And Meta-analysis (DIAGRAM), a case (n = 34,840)-control (n = 114,981) study of T2DM mainly in people of European descent (n = 146,171, 98%), mean age 56.9 years, with genomic control and adjustment for study-specific covariates\textsuperscript{29}. Data on coronary artery disease/myocardial infarction (MI) have been contributed by CARDIoGRAMplusC4D investigators and have been downloaded from www.CARDIOGRAMPLUSC4D.ORG. CARDIoGRAMplusC4D 1000 Genomes-based GWAS is a case (n = 60,801)-control (n = 123,504) study of IHD and MI in people of European (n = 143,485, 77%), South Asian (n = 25,557, 13%), East Asian (n = 11,323, 6%) and Hispanic or African American descent (~4%), we also combined their results for IHD accounting for this overlap using the Lin and Sullivan approach\textsuperscript{47}. CARDIoGRAMplusC4D Metabochip is a case (n = 63,746)-control (n = 130,681) study of IHD mainly in people of European descent (n = 176,892, 91%), mean age 57.4 years, adjusted for age and sex and corrected for genomic control\textsuperscript{27}. When a SNP was not available in CARDIoGRAMplusC4D, genetic associations were obtained from CARDIoGRAM, a more extensively genotyped subset case (n = 22,233)-control (n = 64,762) study of IHD in people of European descent, mean age 58.1 years, with genetic associations similarly adjusted\textsuperscript{28}. Genetic associations for lipids were obtained from the Global Lipids Genetics Consortium (GLGC) which has inverse normal transformed HDL-cholesterol, LDL-cholesterol and triglycerides for 188,577 people of European descent\textsuperscript{31}. MAGIC concerns people mainly of European descent without diabetes and has glycosylated hemoglobin (HbA1c) (%) for 46,368 adults\textsuperscript{32}, fasting glucose (mmol/L) for 133,010 and log-transformed fasting insulin for 108,557 (or if not available, fasting glucose for 46,186 and fasting insulin for 38,238 based on the 2010 version\textsuperscript{27}), homeostatic model assessment (HOMA) $\beta$-cell function for 36,466 and HOMA insulin resistance for 37,037\textsuperscript{27}. Genetic associations for adiposity were obtained from the Genetic Investigation of Anthropometric Traits (GIANT) which has inverse normal transformed BMI (n = 322,154)\textsuperscript{54} and WHR (n = 210,088) for people of European descent\textsuperscript{55}. Genetic associations for adiponectin were obtained from the ADIPOGen Consortium which includes 35,355 people mainly of European descent (n = 29,347, 83%)\textsuperscript{90}. Genetic associations for depression were obtained from the Psychiatric GWAS Consortium (PGC), a case (n = 9,240)-control (n = 9,519) study of major depressive disorder in people of European descent, mean age 45.9 years\textsuperscript{85}. Genetic associations for Alzheimer’s disease were obtained from the International Genomics of Alzheimer’s Project (IGAP), a case (n = 17,008)-control (n = 37,154) study of Alzheimer’s disease in people of European descent, mean age 71.4 years\textsuperscript{31}.

**Genetically predicted childhood cognition (control outcome).** Genetic associations for childhood cognition were obtained from the Social Science Genetic Association Consortium (SSGAC), which has cognition measured by general cognitive ability or intelligence quotient for 17,989 people of European descent\textsuperscript{86}.

**Statistical Analysis.** Genetic associations with T2DM, IHD, CVD risk factors (lipids, glycemic traits, BMI, WHR, and adiponectin), depression, Alzheimer’s disease and childhood cognition (control outcome) were extracted based on the SNPs predicting habitual coffee consumption. Associations of coffee consumption with these outcomes were obtained using weighted generalized linear regression for correlated SNPs\textsuperscript{29}, with a correlation matrix to account for correlation between genetic variants obtained from SNAP using the same catalog as used in the GWAS of the outcome\textsuperscript{28}. Given the two IHD case-control studies overlap (57.5% of the cases and 40.1% of controls)\textsuperscript{47}, we also combined their results for IHD accounting for this overlap using the Lin and Sullivan approach\textsuperscript{43}. Estimates are shown with all genome-wide significant SNPs with potentially pleiotropic effects included and excluded. Estimates are also shown only for non-pleiotropic SNPs known to be functionally relevant to coffee metabolism\textsuperscript{21,22}. As a sensitivity analysis, given the number of outcomes considered, adjustment was also made for multiple comparisons, using a Bonferroni corrected significance level of 0.002 (0.05/18) to account for testing 18 associations (coffee with four disease outcomes, 13 CVD risk factors and one control outcome).

The statistical analyses were conducted using Stata version 13.1 (StataCorp LP, College Station, TX) and R version 3.2.1 (R Foundation for Statistical Computing, Vienna, Austria).
Ethics approval. The methods were carried out in accordance with the approved guidelines. People of predominantly European descent were included in the study. Each study has been specifically approved by the Ethical Committees of the original studies and all the participants provided a written informed consent. This analysis of predominantly European descent were included in the study. Each study has been specifically approved by the Ethical

References

1. National Coffee Association. National Coffee Drinking Trends 2010, http://www.ncausa.org/Industry-Resources/Market-Research/National-Coffee-Drinking-Trends-Report (Date of access: April 28, 2016) (2010).
2. Michaud, D. S. et al. Coffee and tea intake and risk of brain tumors in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort study. Am J Clin Nutr 92, 1145–1150, doi: 10.3945/ajcn.110.230787 (2010).
3. Institute for Scientific Information on Coffee. Can drinking coffee be healthy? Beliefs and behaviours across Europe, http://coffeeandhealth.org/wp-content/uploads/2016/01/Coffee-and-a-Healthy-Diet-European-Infographic-FINAL-1.pdf (2016).
4. United States Department of Health and Human Services & United States Department of Agriculture. 2015–2020 Dietary Guidelines for Americans. 8th Edition. http://health.gov/dietaryguidelines/2015/guidelines/ (Date of access: May 2015) (2015).
5. Lambert, J. C. et al. Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes: a systematic review and a dose-response meta-analysis. Diabetes Care 37, 569–586, doi: 10.2337/dc13-1203 (2014).
6. Liu, Q. P. et al. Habitual coffee consumption and risk of cognitive decline/dementia: A systematic review and meta-analysis of prospective cohort studies. Nutrition 32, 628–636, doi: 10.1016/j.nut.2015.11.015 (2016).
7. Grosso, G., Micek, A., Castellano, S., Pajak, A. & Galvano, F. Coffee, tea, caffeine and risk of depression: A systematic review and dose-response meta-analysis of observational studies. Mol Nutr Food Res 60, 223–234, doi: 10.1002/mnr.201500620 (2016).
8. Liu, J. N. et al. Coffee consumption and risk of coronary heart diseases: a meta-analysis of 21 prospective cohort studies. Int J Cardiol 137, 216–225, doi: 10.1016/j.ijcard.2008.06.051 (2009).
9. Nordestgaard, A. T., Thomsen, M. & Nordestgaard, B. G. Coffee intake and risk of obesity, metabolic syndrome and type 2 diabetes: a randomized controlled trial. Nutr J 10, 93, doi: 10.1186/1475-2891-10-93 (2011).
10. Persson, J. et al. Sex-specific effects of Adiponectin on Carotid Intima-Media Thickness and Incident Cardiovascular Disease. J Am Heart Assoc 4, e001853, doi: 10.1161/JAHA.114.001853 (2015).
11. Ohnaka, K. et al. Effects of 16-week consumption of decaffeinated and decaffeinated instant coffee on glucose metabolism in a randomized controlled trial. J Nutr Metab 2012, 207426, doi: 10.1155/2012/207426 (2012).
12. Correa, T. A. et al. Paper-based filtered coffee increases cholesterol and inflammation biomarkers independent of roasting degree: a clinical trial. Nutrition 29, 977–981, doi: 10.1016/j.nut.2013.01.003 (2013).
13. Kemp, K. et al. Cardiometabolic effects of two coffee blends differing in content for major constituents in overweight adults: a randomized controlled trial. Eur J Nutr 54, 845–854, doi: 10.1007/s00394-014-0763-3 (2015).
14. Lawlor, D. A., Harbord, R. M., Sterne, J. A., Timpson, N. & Davey Smith, G. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Stat Med 27, 1133–1163, doi: 10.1002/sim.3034 (2008).
15. Nordestgaard, A. T., Thomasen, M. & Nordestgaard, B. G. Coffee intake and risk of obesity, metabolic syndrome and type 2 diabetes: a Mendelian randomization study. Int J Epidemiol 44, 551–565, doi: 10.1093/ije/dyv083 (2015).
16. Drewnowski, A. & Rehm, C. D. Sources of caffeine in Diets of US Children and Adults: Trends by Beverage Type and Purchase Location. Nutrients 8, doi: 10.3390/nu8030154 (2016).
17. The Coffee and Caffeine Genetics Consortium et al. Genome-wide meta-analysis identifies six novel loci associated with habitual coffee consumption. Mol Psychiatry 20, 647–656, doi: 10.1038/mp.2014.107 (2015).
18. Corneliis, M. C. et al. Genome-wide meta-analysis identifies regions on 7p21 (AHR) and 15q24 (CYP1A2) as determinants of habitual caffeine consumption. PLoS Genet 7, e1002033, doi: 10.1371/journal.pgen.1002033 (2011).
19. Amin, N. et al. Genome-wide association analysis of coffee drinking suggests association with CYP1A1/CYP1A2 and NRCAM. Mol Psychiatry 17, 1116–1129, doi: 10.1038/mp.2011.102 (2012).
20. Ebrahim, S. & Davey Smith, G. Mendelian randomization: can genetic epidemiology help redress the failures of observational epidemiology? Hum Genet 123, 15–33, doi: 10.1007/s00439-007-0448-6 (2008).
21. Mattar, R., de Campos Mazo, D. F. & Carrilho, F. J. Lactose intolerance: diagnosis, genetic, and clinical factors. Clin Exp Gastroenterol 5, 113–121, doi: 10.2147/CEG.S32368 (2012).
22. Haycock, P. C. et al. Best (but oft-forgotten) practices: the design, analysis, and interpretation of Mendelian randomization studies. Am J Clin Nutr 103, 965–978, doi: 10.3945/ajcn.115.118216 (2016).
23. Pierce, B. L. & Burgess, S. Efficient design for Mendelian randomization studies: subsample and 2-sample instrumental variable estimators. Am J Epidemiol 178, 1177–1184, doi: 10.1093/aje/kwt084 (2013).
24. CARDIoGRAMplusCaucasian Consortium et al. Large-scale association analysis identifies new loci for coronary artery disease. Nat Genet 45, 23–33, doi: 10.1038/ng2480 (2013).
25. Schunkert, H. et al. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet 43, 333–338, doi: 10.1038/ng.784 (2011).
26. Morris, A. P. et al. Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nat Genet 44, 981–990, doi: 10.1038/ng.2383 (2012).
27. Major Depressive Disorder Working Group of the Psychiatric Gwas Consortium et al. A mega-analysis of genome-wide association studies for major depressive disorder. Mol Psychiatry 18, 497–511, doi: 10.1038/mp.2012.21 (2013).
28. Lambert, J. C. et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease. Nat Genet 45, 1452–1458, doi: 10.1038/ng.2802 (2013).
29. Ritchie, K. et al. The neuroprotective effects of caffeine: a prospective population study (The Three City Study). Neurology 69, 536–545, doi: 10.1212/01.wnl.0000266670.15221.0e (2007).
30. Global Lipids Genetics Consortium et al. Discovery and refinement of loci associated with lipid levels. Nat Genet 45, 1274–1283, doi: 10.1038/ng.2797 (2013).
31. Scott, R. A. et al. Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways. Nat Genet 44, 991–1005, doi: 10.1038/ng.2385 (2012).
32. Soranzo, N. et al. Common variants at 10 genomic loci influence hemoglobin A1c levels via glycemic and nonglycemic pathways. Diabetes 59, 3229–3239, doi: 10.2337/db10-0502 (2010).
33. Schooling, C. M., Au Yeung, S. L. & Freeman, G. Mendelian randomization estimates may be inflated. J Am Coll Cardiol 61, 1931, doi: 10.1016/j.jacc.2012.12.049 (2013).
37. Burgess, S. et al. Using published data in Mendelian randomization: a blueprint for efficient identification of causal risk factors. *Eur J Epidemiol* **30**, 543–552, doi: 10.1007/s10654-015-0011-z (2015).

38. Moran, A. E. et al. Variations in ischemic heart disease burden by age, country, and income: the Global Burden of Diseases, Injuries, and Risk Factors 2010 study. *Glob Heart* **9**, 91–99, doi: 10.1016/j.gheart.2013.12.007 (2014).

39. Danai, G. et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. *Lancet* **378**, 31–40, doi: 10.1016/S0140-6736(11)60679-X (2011).

40. Fulgoni, V. L. 3rd, Keast, D. R. & Lieberman, H. R. Trends in intake and sources of caffeine in the diets of US adults: 2001–2010. *Am J Clin Nutr* **101**, 1081–1087, doi: 10.3945/ajcn.113.068077 (2015).

41. Schooling, C. M., Freeman, G. & Cowling, B. J. Mendelian randomization and estimation of treatment efficacy for chronic diseases. *Am J Epidemiol* **177**, 1128–1133, doi: 10.1093/aje/kws344 (2013).

42. Davey Smith, G. & Ebrahim, S. Mendelian randomization: prospects, potentials, and limitations. *Int J Epidemiol* **33**, 30–42, doi: 10.1093/ije/dyh132 (2004).

43. Strandhagen, E. & Thelle, D. S. Filtered coffee raises serum cholesterol: results from a controlled study. *Eur J Clin Nutr* **57**, 1164–1168, doi: 10.1038/sj.ejcn.1601668 (2003).

44. Rowland, A. & Mangoni, A. A. Cytochrome P450 and ischemic heart disease: current concepts and future directions. *Expert Opin Drug Metab Toxicol* **10**, 191–213, doi: 10.1517/17425255.2014.859675 (2014).

45. Dragen, N. et al. Phenotype of the Cyp1a1/1a2/1b1-/- triple-knockout mouse. *Mol Pharmacol* **73**, 1844–1856, doi: 10.1124/mol.108.045658 (2008).

46. Wada, T. et al. Aryl Hydrocarbon Receptor Plays Protective Roles against High Fat Diet (HFD)-induced Hepatic Steatosis and the Subsequent Lipotoxicity via Direct Transcriptional Regulation of Socs3 Gene Expression. *J Biol Chem* **291**, 7064–7076, doi: 10.1074/jbc.M115.693655 (2016).

47. Nikpay, M. et al. A comprehensive 1,000 Genomes-based genome-wide association meta-analysis of coronary artery disease. *Nat Genet* **47**, 1121–1130, doi: 10.1038/ng.3396 (2015).

48. Solfrizzi, V. et al. Coffee Consumption Habits and the Risk of Mild Cognitive Impairment: The Italian Longitudinal Study on Aging. *J Alzheimers Dis* **47**, 889–899, doi: 10.3233/JAD-150335 (2015).

49. Solfrizzi, V. et al. Lifestyle-related factors in predementia and dementia syndromes. *Expert Rev Neurother* **8**, 133–158, doi: 10.1586/14737175.8.1.133 (2008).

50. Panza, E. et al. Coffee, tea, and caffeine consumption and prevention of late-life cognitive decline and dementia: a systematic review. *J Nutr Health Aging* **19**, 313–328, doi: 10.1007/s12603-014-0563-8 (2015).

51. Santos, C., Costa, J., Santos, J., Vaz-Carneiro, A. & Lunet, N. Caffeine intake and dementia: systematic review and meta-analysis. *J Alzheimers Dis* **20** Suppl 1, S187–S204, doi: 10.3233/JAD-2010-091387 (2010).

52. Araujo, L. F. et al. Association of Coffee Consumption with MRI Markers and Cognitive Function: A Population-Based Study. *J Alzheimers Dis*, doi: 10.3233/JAD-160116 (2016).

53. Linder, A. E. et al. Vascular reactivity, 5-HT uptake, and blood pressure in the serotonin transporter knockout rat. *Am J Physiol Heart Circ Physiol* **294**, H1745–H1752, doi: 10.1152/ajpheart.91415.2007 (2008).

54. Tajedlina, W. et al. Association of Platelet Serotonin Levels in Alzheimer’s Disease with Clinical and Cerebrospinal Fluid Markers. *J Alzheimers Dis* , doi: 10.3233/JAD-160022 (2016).

55. Higdon, J. V. & Frei, B. Coffee and health: a review of recent human research. *Crit Rev Food Sci Nutr* **46**, 101–123, doi: 10.1080/10408699.2007.998576 (2006).

56. Ohbo, G., Agunloye, O. M., Akinyemi, A. J., Ademiluyi, A. O. & Adelegba, S. A. Comparative study on the inhibitory effect of caffeic and chlorogenic acids on key enzymes linked to Alzheimer’s disease and some pro-oxidant induced oxidative stress in rats’ brain: in vitro. *Neurochem Res* **38**, 413–419, doi: 10.1007/s11064-012-0935-6 (2013).

57. Dupuis, J. et al. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. *Nat Genet* **42**, 105–116, doi: 10.1038/ng.520 (2010).

58. Locke, A. E. et al. Genetic studies of body mass index yield new insights for obesity biology. *Nature* **518**, 197–206, doi: 10.1038/ nature14177 (2015).

59. Shungin, D. et al. New genetic loci link adipose and insulin biology to body fat distribution. *Nature* **518**, 187–196, doi: 10.1038/nature14132 (2015).

60. Dastani, Z. et al. Novel loci for adiponectin levels on their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals. *PLoS Genet* **8**, e1002607, doi: 10.1371/journal.pgen.1002607 (2012).

61. Benjamin, B. et al. Childhood intelligence is heritable, highly polygenic and associated with FBNP1L. *Mol Psychiatry* **19**, 253–258, doi: 10.1038/mp.2012.184 (2014).

62. Burgess, S., Dudbridge, F. & Thompson, S. G. Combining information on multiple instrumental variables in Mendelian randomization: comparison of allele score and summarized data methods. *Stat Med* **35**, 1880–1906, doi: 10.1002/sim.6835 (2016).

63. Han, B. et al. A general framework for meta-analyzing dependent studies with overlapping subjects in association mapping. *Hum Mol Genet* **19**, 1–10, doi: 10.1093/hmg/ddw049 (2016).

Acknowledgements
The authors thank the Coffee and Caffeine Genetics Consortium, CARDIoGRAMplusC4D, DIAGRAM, GIANT, GLGC, ADIPOGen, MAGIC, PGC, IGAP and SSGAC Consortia for access to their GWAS data.

Author Contributions
M.K. Kwok performed the literature review, conducted data analysis, interpreted findings and drafted the manuscript. G.M. Leung interpreted findings and critically reviewed the manuscript. C.M. Schooling conceptualized ideas, designed and directed analytic strategy, interpreted findings, revised drafts of the manuscript critically and supervised the study from conception to completion.

Additional Information
Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Kwok, M. K. et al. Habitual coffee consumption and risk of type 2 diabetes, ischemic heart disease, depression and Alzheimer’s disease: a Mendelian randomization study. *Sci. Rep.* **6**, 36500; doi: 10.1038/srep36500 (2016).

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
